Wells Fargo
VIRX

Wells Fargo’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Wells Fargo’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-171
Closed -$28 – 7365
2024
Q4 		$28 Hold
171
– – ﹤0.01% 6628
2024
Q3 		$40 Hold
171
– – ﹤0.01% 6392
2024
Q2 		$93 Sell
171
-214
-56% -$169 ﹤0.01% 6259
2024
Q1 		$392 Buy
385
+3
+0.8% +$2 ﹤0.01% 6334
2023
Q4 		$217 Buy
382
+12
+3% +$7 ﹤0.01% 6587
2023
Q3 		$385 Buy
370
+27
+8% +$37 ﹤0.01% 6418
2023
Q2 		$484 Buy
343
+8
+2% +$11 ﹤0.01% 6496
2023
Q1 		$533 Buy
335
+3
+0.9% +$5 ﹤0.01% 6541
2022
Q4 		$485 Buy
332
+6
+2% +$18 ﹤0.01% 6396
2022
Q3 		$2K Buy
326
+23
+8% +$97 ﹤0.01% 6219
2022
Q2 		$1K Sell
303
-64,731
-100% -$184K ﹤0.01% 6656
2022
Q1 		$310K Sell
65,034
-10,825
-14% -$32.6K ﹤0.01% 4726
2021
Q4 		$277K Buy
75,859
+65,457
+629% +$349K ﹤0.01% 5077
2021
Q3 		$83K Buy
10,402
+8,688
+507% +$85.6K ﹤0.01% 5456
2021
Q2 		$19K Sell
1,714
-6,232
-78% -$62.5K ﹤0.01% 5929
2021
Q1 		$73K Sell
7,946
-3,299
-29% -$34.4K ﹤0.01% 5633
2020
Q4 		$78K Sell
11,245
-4,933
-30% -$25.7K ﹤0.01% 5447
2020
Q3 		$71K Buy
16,178
+4,558
+39% +$39.8K ﹤0.01% 5387
2020
Q2 		$107K Sell
11,620
-10,094
-46% -$152K ﹤0.01% 5196
2020
Q1 		$315K Sell
21,714
-10,073
-32% -$219K ﹤0.01% 4385
2019
Q4 		$376K Sell
31,787
-83
-0.3% -$1.39K ﹤0.01% 4581
2019
Q3 		$803K Sell
31,870
-6,449
-17% -$186K ﹤0.01% 4013
2019
Q2 		$975K Buy
38,319
+11,463
+43% +$443K ﹤0.01% 3879
2019
Q1 		$1.14M Buy
26,856
+25,163
+1,486% +$570K ﹤0.01% 3778
2018
Q4 		$25K Sell
1,693
-1,054
-38% -$43K ﹤0.01% 5722
2018
Q3 		$192K Sell
2,747
-1,157
-30% -$87.9K ﹤0.01% 5029
2018
Q2 		$290K Buy
3,904
+2,065
+112% +$184K ﹤0.01% 4825
2018
Q1 		$175K Buy
1,839
+510
+38% +$87.5K ﹤0.01% 5048
2017
Q4 		$171K Sell
1,329
-1,392
-51% -$130K ﹤0.01% 5041
2017
Q3 		$185K Buy
2,721
+1,525
+128% +$125K ﹤0.01% 4971
2017
Q2 		$113K Buy
1,196
+522
+77% +$59.9K ﹤0.01% 5112
2017
Q1 		$96K Buy
674
+213
+46% +$30.5K ﹤0.01% 5221
2016
Q4 		$58K Buy
461
+191
+71% +$26.6K ﹤0.01% 5340
2016
Q3 		$41K Buy
270
+234
+650% +$33K ﹤0.01% 5380
2016
Q2 		$4K Buy
36
+1
+3% +$111 ﹤0.01% 5861
2016
Q1 		$4K Hold
35
– – ﹤0.01% 5923
2015
Q4 		$6K Sell
35
-17
-33% -$3.18K ﹤0.01% 5854
2015
Q3 		$9K Sell
52
-6
-10% -$2.17K ﹤0.01% 5740
2015
Q2 		$36K Buy
58
+13
+29% +$6.91K ﹤0.01% 5430
2015
Q1 		$24K Buy
45
+10
+29% +$5.04K ﹤0.01% 5318
2014
Q4 		$19K Sell
35
-597
-94% -$269K ﹤0.01% 5386
2014
Q3 		$947K Buy
632
+565
+843% +$818K ﹤0.01% 3509
2014
Q2 		$92K Buy
67
+16
+31% +$18.6K ﹤0.01% 4718
2014
Q1 		$71K Buy
51
+37
+264% +$43K ﹤0.01% 4805
2013
Q4 		$14K Sell
14
-4
-22% -$4.14K ﹤0.01% 5119
2013
Q3 		$19K Sell
18
-10
-36% -$10.7K ﹤0.01% 4971
2013
Q2 		$30K Buy
+28
New +$31.2K ﹤0.01% 4762

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Wells Fargo's VIRX Position: Q1 2025 in Review

Wells Fargo sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 171 shares — an estimated $28 sold.

Wells Fargo first reported a position in VIRX in Q2 2013 and held it in 47 quarters. The position peaked at $1.14M in Q1 2019. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Wells Fargo reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Wells Fargo sold 171 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $28.
  • Wells Fargo first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 47 quarters.
  • Wells Fargo's Viracta Therapeutics, Inc. Common Stock position peaked at $1.14M in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Wells Fargo's 13F filing for Q1 2025, filed 13 May 2025.